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Abstract: Breast cancer is characterized by an uncontrolled growth of cells in breast tissue. 
Genes that foster cell growth in breast cells are overexpressed, giving rise to breast tumors. 
The identification of effective inhibitors represents a rational chemopreventive strategy. The 
current in silico study provides a pharmacoinformatic approach for the identification of active 
compounds against a co-chaperone HSP90 and the human epidermal growth factor receptors 
EGFR and HER2/neu receptor. The elevated levels of expression of these target proteins have 
been documented in breast cancer. The utilization of drug-likeness filters helped to evaluate 
the pharmacological activity of potential lead compounds. Those fulfilling this criterion were 
subjected to energy minimization for 1000 steepest descent steps at a root means square gradi-
ent of 0.02 with an Amber ff12SB force field. Based on molecular docking results and binding 
interaction analysis, this study represents five chemical compounds (S-258282355, S-258012947, 
S-259417539, S-258002927, and S-259411474) that indicate high binding energies that range 
between −8.7 to −10.3 kcal/mol. With high cytochrome P inhibitory promiscuity activity, these 
multi-targeted potential hits portray not only good physiochemical interactions but also an excel-
lent profile of absorption, distribution, metabolism, excretion, and toxicity, which hypothesizes 
that these compounds can be developed as anticancer drugs in the near future.
Keywords: EGFR, metastasis, TNBC, HER2, heat shock proteins
Introduction
Breast cancer is characterized by the uncontrolled growth of cells forming a hard 
painless lump in the breast tissue, usually in the milk ducts or lobules that provide 
them with milk.1,2 The most common practice to classify breast tumors is according 
to the status of three specific cell surface receptors: the estrogen receptor (ER), the 
progesterone receptor, and the human epidermal growth factor (EGF) receptor HER2/
neu receptor. Approximately 75% of all breast cancers are hormone receptor-positive.3 
HER2-positive breast cancer accounts for 20–30% of hormone receptor-positive breast 
cancer that relates to the overexpression of HER2/neu protein. A rare form of breast 
cancer, triple-negative breast cancer (TNBC), comprises tumors cells that lack recep-
tors for estrogen and progesterone and do not overexpress the HER2 protein. 
One of the factors that has been shown to increase a woman’s risk of developing 
breast cancer is age.4 Breast cancer in women has been observed to occur at or over the 
age of 50. A positive personal or family history is also known to pose an increased risk 
of developing breast cancer. In addition, a long menstrual life or the use of hormone 
replacement therapy after menopause increases the risk of developing breast cancer.5
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Growth factors and their receptors play pivotal roles 
in the regulation of epithelial cell growth and differentia-
tion.6 The HER/erbB family of receptors includes the EGF 
receptor (EGFR, HER1, and erbB-1), the orphan HER2/neu 
(erbB-2), and the neuregulin/neuregulin receptors HER3 
(erbB-3) and HER4 (erbB-4). Increased knowledge about 
the pathophysiological mechanisms of breast cancer has led 
to exponential growth in the identification of biomolecular 
markers. In this study, a rational approach has been utilized 
to research the more widely recognized molecular targets 
in breast cancer. Although there are FDA-approved drugs 
for breast cancer treatment, their use is accompanied by 
various side effects. Therefore, it is important to devise an 
alternative treatment that not only treats the tumor but also 
has no side effects.
Members of EGF family specifically interact with the 
EGF receptor (EGFR), which is a cell surface receptor.7 
Binding of specific ligands such as EGF and transforming 
growth factor α activates EGFR. PI3 kinase, Ras-Raf-
MAPK, JNK, and PLCγ mediate the major EGFR signal-
ing pathways.8,9 Loss of cell polarization is one of the main 
features observed when most of the members of the EGFR 
family are activated, leading to scattering and invasion of 
breast epithelial cells.10 Metastasis and angiogenesis pro-
cesses have been found to be linked with the dysregulation 
of EGFR pathways. Furthermore, in many human malig-
nancies, this has been observed to be the reason behind 
the poor prognosis.11–13 One of the mechanisms of EGFR 
overexpression is an amplification of the EGFR gene, which 
has been implicated in oligodendroglioma,14 glioblastoma, 
lung cancer,15 gastric cancer, and breast cancer.16 In breast 
cancers, EGFR gene amplification has been observed in 
0.8–14% of tumors.17,18 However, gene amplification has 
been shown in ~25% of cases of metaplastic breast cancer 
– a specific phenotype of TNBC.19,20
The neu gene encodes a protein HER2, similar in 
structure as human EGFR.21,22 The HER2 receptor plays a 
significantly important role in the cell growth and differ-
entiation process, an overexpression of which is associated 
with the development of human cancers including breast, 
ovarian, and gastrointestinal (GI) tract cancers.23,24 HER2 is 
overexpressed in 15–30% of invasive breast cancers, which 
has both prognostic and predictive implications. A 40- to 
100-fold increase in the expression of HER2 protein results 
in the tumor cell surface containing ~2 million receptors. 
Approximately 20–50 HER2-gene copies have been found 
in breast cancers.25 HER2 gene amplification is associated 
with shorter disease-free and overall survival in breast cancer. 
The prognostic significance of HER2 amplification has been 
established in 189 human breast cancers.26 HER2 amplifica-
tion is one of the early events in human breast tumorigenesis. 
As per evidence, during progression to invasive disease and 
nodal or distant metastasis, HER2 status is maintained.27 An 
increased resistance to certain hormonal agents, enhanced 
propensity to metastasize to the brain, and high sensitivity 
to certain cytotoxic chemotherapeutic agents have been 
found to be associated with breast cancers resulting from an 
overexpression of HER2.28
Heat shock proteins (HSPs) are members of the molecular 
chaperones that play an essential role in the folding of cellular 
proteins.29,30 Furthermore, through inhibition of programmed 
cell death and cell senescence during hyperthermia, HSPs 
directly participate in cell survival.31–33 In carcinogenesis, 
HSPs have a role in helping cells (a) to escape tumor sup-
pression pathways, (b) in becoming treatment resistant, (c) in 
progressing to an advanced stage of cancer, and (d) for facili-
tating metastasis.34 Tumor suppressor protein (p53), ER, HIF-
1alpha, Raf-1 MAP kinase, and a variety of receptor tyrosine 
kinases, such as HER2, bind with HSP90. These interactions 
play a key role in breast neoplasia.35 Breast ductal carcinomas 
indicate an increased HSP90 expression,36–38 whereas lobu-
lar carcinomas and lobular neoplasia manifest significantly 
decreased HSP90 expression.39 Breast cancer cells become 
resistant to stress stimuli through HSP90 overexpression. 
Therefore, therapeutic opportunities in treating cancer can 
be devised by the pharmacological inhibition of these targets.
In silico approaches have paved the way to solve many 
biological problems,40–42 which have led to the identification 
of novel inhibitors against numerous diseases.43–47 In this 
investigation, active compounds against these three targets 
were screened by structure-based virtual screening (VS) to 
identify potential virtual hits. The molecular docking tool, 
AutoDockVina (AD Vina),48 was used to dock 50 filtered 
compounds against EGFR, HER2, and HSP90. The ligands 
were also analyzed for their profile of absorption, distribution, 
metabolism, excretion, and toxicity (ADMET), which deter-
mined the ADMET efficiency of the drug. Potential hits that 
indicate good pharmacokinetic (PK) and pharmacodynamic 
(PD) properties have a better chance to be future drugs. The 
results of the current study concluded that five multi-targeted 
compounds with high binding energies as well as a good 
ADMET profile against all three targets be taken into consid-
eration, suggesting them as potential hits for drug development 
against breast cancer after testing through in vitro experiments.
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Materials and methods
Binding-site analysis
High-resolution crystals with experimentally identified 
drug sites for EGFR, HSP90, and HER2 were used. Bind-
ing pockets of these proteins were examined from crystal 
structures and were further evaluated using the CASTp server 
(Computed Atlas of Surface Topography of Proteins).49 It 
locates all likely binding pockets, and the algorithm criti-
cally determines the binding pocket and possible cavities in 
a solvent-accessible surface area.
Protein dataset
X-ray crystallographic structures of EGFR (Protein Data 
Bank [PDB] ID: 1M17) in complex with the 4-anilinoquin-
azoline inhibitor erlotinib (resolution: 2.6 Å; R-value free: 
0.295), HSP90 complexed with ganetespib (PDB ID: 3TUH; 
resolution: 1.8 Å; R-value free: 0.213), and HER2 in complex 
with TAK-285 (PDB ID: 3RCD; resolution: 3.21 Å; R-value 
free: 0.294) were retrieved from PDB. The criteria for choos-
ing PDBs were (a) minimum resolution and (b) conforma-
tion of docked ligand being the same as in the crystallized 
structure after the redocking procedure.
Protein preparation
To prepare the selected proteins for docking, co-crystallized 
water molecules, small molecules, nonpolar hydrogens, lone 
pairs, and nonstandard residues were deleted, and hydrogens 
and Gasteiger charges were added and merged. Energy 
minimization and geometry optimization of all structures 
were performed using Dock Prep, a built-in tool for preparing 
structures before docking, in UCSF Chimera 10.1 (Resource 
for Biocomputing, Visualization, and Informatics, University 
of California San Francisco, San Francisco, CA, USA). The 
energy was minimized for the 1000 steepest descent steps at a 
root means square gradient of 0.02, an update interval of 10, 
and with an Amber ff12SB force field using UCSF Chimera 
10.1.50  Furthermore, incomplete side chains were repaired 
using the Dunbrack rotamer library. Hydrogens were added 
to reasonably generate protonation states at physiological pH. 
Potentially ambiguous or rare protonation states, especially 
in binding sites and nonstandard residues, were verified and 
corrected before charges were added. Charges were added to 
assign partial charges to atoms. Partial charges were assigned 
as an atom attribute named charge and included in the Mol2 
file (molecule model 3D atomic coordinate files and metadata).
Preparation of chemical library
E-molecule databases and chemical companies including Pub-
Chem and Active ZINC were ultilized for literature analysis. All 
information on chemical compounds was merged, thus obtain-
ing an overall database of ~3 million chemical  compounds. 
Duplicated structures were removed to acquire new scaffolds 
through InChlKey generated by open babel. Drugs present-
ing poor PK properties failed to continue progression in the 
drug development process. The compounds were checked for 
their oral bioavailability alongside PK parameters such as the 
blood–brain barrier (BBB), better human intestinal absorption 
(HIA), good solublity, and low toxicity through the applica-
tion of Lipinski’s Ro5 (LRo5).40 Compounds violating this 
rule were eliminated from the study. Using Open Bable, the 
two-dimensional (2D) files of structures that followed this 
criteria were transformed into three-dimensional (3D) format 
and saved as molecule files. Discovery Studio® (DS) visualizer 
(Accelrys Inc., San Diego, CA, USA)51 was used for energy 
minimization during the preparation of ligand molecules.
Virtual screening
VS is a computational technique used to screen potential 
compounds against specific target protein from chemical 
compound libraries. The aim was to reduce the number 
of druggable compounds, inhibiting target proteins more 
efficiently, to a manageable number. Structure-based virtual 
screening (SBVS) was utilized to screen substantial databases 
in the quest of finding novel and potential lead compounds. 
SBVS estimates the likelihood of a ligand to bind efficiently 
to the target protein. It involves the application of a scoring 
function preceeding docking of candidate ligands into a 
protein target with high binding energies.
In the current study, the drug discovery platform Mcule 
was utilized to employ SBVS.52 For this, an Mcule database 
of filtered compounds was created manually. Mcule48 has a 
built-in AD Vina tool, which was used to perform molecular 
docking. In SBVS, molecular docking predicts the binding 
conformation of small-molecule ligands to the binding site of 
the selected target. Characterization of the binding behavior 
plays an essential role in the rational design of drugs as well as 
to elucidate fundamental biochemical processes. Before VS, 
an in-depth analysis of the protein structures was performed 
to understand the binding pocket of target proteins. Using the 
AutoGrid program of Chimera, a grid map with dimensions 
of 30 × 30 × 30 Å was generated that covered the binding 
pocket of each protein. For SBVS, each ligand was docked 
in the respective binding site of EGFR, HER2, and HSP90, 
and was scored by maximum binding affinity.
in silico aDMeT assessment
Prediction of the ADMET profile for drug candidates and 
environmental chemicals plays a major role in drug  discovery 
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and environmental hazard assessment. Top virtual hits from 
VS against each protein were further filtered through PK 
and PD parameters and evaluation of favorable ADMET 
parameters. To identify the possible adverse effects of these 
compounds in humans, the ADMET properties of the filtered 
compounds were predicted using various tools that include 
the OSIRIS property explorer (Actelion Pharmaceuticals 
Ltd., Allschwil, Switzerland) which highlights undesired 
effects if posed by the compound being analyzed, admetSAR 
(http://lmmd.ecust.edu.cn:8000/) for prediction of quantita-
tive structure–activity relationship-based ADMET properties, 
and Molsoft (Molsoft LLC, La Jolla, CA, USA) for calcula-
tion of drug-likeness properties. ADMET parameters include 
the BBB, HIA, P-glycoprotein substrates and inhibitors, renal 
organic cation transporter (ROCT), cytochrome P (CYP) 
inhibitory promiscuity, and toxicity risks.
Results and discussion
The aim of the current study was to elucidate alternative 
inhibitory compounds against EGFR, HER2, and HSP90 pro-
teins. In silico VS of ~3 million compounds was performed by 
establishing a pipeline of LRo5 and PK properties to assess 
drug likeness. Compounds that showed a strong binding 
affinity for EGFR, HER2, and HSP90 proteins were selected 
for further investigations. Further, the ADMET profile was 
analyzed to filter top hits to identify suitable virtual hit candi-
date compounds. The current in silico study was undertaken 
to identify efficient anti-breast cancer compounds. The five 
multi-targeted top compounds were also evaluated for their 
PK and PD properties. The virtual hits identified in this study 
can be used as an alternative targeting agent for breast cancer 
after being tested through in vitro experiments.
Binding-site evaluation
The crystal structure of the kinase domain of the EGFR 
in complex with 4-anilinoquinazoline inhibitor erlotinib 
(PDB ID: 1M17) was obtained from PDB. It was found that 
residues Leu694, Leu768, Met769, Gly772, and Leu820 
formed significant interactions with the inhibitor. The crys-
tal structure of HER2 complexed with TAK-285 (PDB ID: 
3RCD) indicated Ala751, Leu800, Met801, Leu852, and 
Asp863 to be among the significant interacting residues. 
The X-ray co-crystallized structure of TAK-285 with HER2 
demonstrated that it interacts with the expected residues 
in the respective ATP pocket. HSP90 complexed with 
ganetespib (PDB ID: 3TUH) indicated that the residues 
Asn51, Lys58, Asp93, Gly97, and Thr184 form significant 
interactions at the binding site. The binding-site residues 
of all three target proteins were also confirmed by using 
CASTp. Binding-site interacting residues, as reported in 
the PDB, are shown in Figure 1.
structure-based virtual screening
To identify anti-breast cancer compounds, a database of ~3 
million compounds was screened by the application of a series 
of filters (LRo5, drug likeness, PK filters), which led us to 
select the top 66, 832 best compounds. These compounds were 
subjected to SBVS against EGFR, HER2, and HSP90 sepa-
rately to identify multi-targeted compounds common among 
all these targets. The flowchart of multistep VS is shown in 
Figure 2. The docking compounds were ranked based on their 
highest binding energy with the corresponding protein. To 
identify potential hits having binding affinities greater than 
the reported co-crystallized inhibitor, binding energy cutoffs 
of −8.9, −8.5, and −8.3 kcal/mol were set against EGFR, 
HER2, and HSP90, respectively, after redocking with the 
reported co-crystallized inhibitor as deposited in the PDB to 
select only those hits which were above that specific threshold. 
Only top-ranked hits with higher binding energy for all three 
proteins were considered and investigated further.
Binding energy cutoff value was applied for VS to 
select only the high-ranked compounds. A total of 96 hits 
with binding energies lower than −8.9 kcal/mol for EGFR, 
114 hits with <−8.5 kcal/mol for HER2, and 79 hits with 
<−8.3 kcal/mol for HSP90 were chosen based upon the AD 
Vina docking score (∆G). Visual inspection was carried 
out to screen these 289 compounds further. As a result, 71 
compounds with promising high binding energies against 
all three targets were selected. An extensive ADMET 
analysis was performed to screen these virtual hits, and 
their molecular interactions with binding-site residues were 
carefully analyzed.
Prediction of aDMeT properties
Molecular descriptors are the deciding factor for PK proper-
ties and toxicity of a compound. ADMET properties predicted 
in silico identify the likelihood of compounds to be used as 
human therapeutic agent.53 The admetSAR online server was 
utilized for calculating the ADMET properties of 71 common 
compounds of all three proteins. It is important for compounds 
to have a promising ADMET profile. The BBB,54 HIA,55 
aqueous solubility,56 Caco-2 cell permeability, CYP450 inhibi-
tion,57 and Ames toxicity were calculated for 71 compounds. 
It was observed that only 15 virtual hits were successful at 
passing through these ADMET filters. These 15 virtual hits 
were further filtered through a series of drug safety profiling 
parameters. Undesirable moieties and substructures causing 
potential toxicity were eliminated through a series of PAINS 
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(pan assay interference compounds) filters. Among the 15, 
only five compounds were unidentified by PAINS-1, -2, and -3.
The admetSAR predictions indicated that the ability 
to penetrate the BBB and HIA was portrayed by all com-
pounds; in addition, all the compounds were revealed as 
non-inhibitors of the P-gp inhibitor except S-258002927. 
None of the compounds indicated any inhibitory effects 
on the ROCT. CYP enzymes, including various CYP450 
substrates and inhibitors, play a fundamental role in drug 
metabolism. The results showed that most compounds 
were non-inhibitors of CYP450 enzymes. A significant 
finding was observed for compounds S-258012947 and 
S-258002927 that indicated low CYP-inhibitory promiscu-
ity, being non-inhibitors of all CYP450 enzymes including 
1A2, 2C9, 2D6, 2C19, and 3A4. Further drug metabolism 
analyses showed these compounds were non-substrates of 
two CYP450 substrates (2C9 and 2D6). The ADMET prop-
erties of the top five best virtual hits as common against all 
three targets are tabulated in Table 1, and their 2D structures 
are presented in Figure 3.
Figure 1 (A) epidermal growth factor receptor (egFr) tyrosine kinase domain with 4-anilinoquinazoline inhibitor erlotinib. (B) novel her2/egFr dual. inhibitors bearing 
a pyrrolo[3,2-d] pyrimidine scaffold. (C) The crystal structure of the n-terminal domain of an hsP90 in the presence of an inhibitor ganetespib. 
Notes: green dashed lines indicate hydrogen bonds with distance in angstrom (Å), spoked red arcs indicate hydrophobic contacts, atoms are shown in black for carbon, 
blue for nitrogen, red represents oxygen, yellow represents sulfur, and green represents fluorine.
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Molecular docking studies of egFr
All five compounds showed high binding energies with 
EGFR ranging from −8.9 to −9.7 kcal/mol with AD Vina, as 
presented in Table 2. All compounds established a network 
of molecular interactions (H-bonds, Van der Waals [VdW], 
alkyl, π-alkyl, and π-sigma bonds) with the active-site 
residues of EGFR when analyzed in 2D plots as shown in 
Figure 4. S-259417539 formed various binding interac-
tions including H-bonds (Thr766), π-alkyl (Ala719), alkyl 
(Val702), and VdW (Leu694, Cys751, Asp831, Lys721, 
Leu764, Met742, Glu738, Asn818, Arg817). S-259411474 
established H-bond and alkyl bond with Met769 and Leu820, 
π-alkyl with Ala719 and Val702, and VdW interactions with 
Ile720, Ile765, Leu768, Leu764, Leu753, Thr830, Asp831, 
Gly695, Glu738, Cys773, Phe699, and Gly772, respectively. 
Likewise, S-258012947 was involved in various binary 
interactions including H-bond (Asp831), π-alkyl (Leu694), 
and VdW (Ile720, Ile765, Cys773, Leu834, Gly833, and 
Thr765), whereas S-258282355 and S-258002927 were 
found to interact with Asn818 and Asp831 through H-bond, 
with residues Leu694, Leu820, and Val702 by forming alkyl 
bonds, and with residues Arg817, Thr766, Gln767, Leu768, 
Met769, Gly772, and Cys773, and Gly695, Gly772, Arg817, 
Cys773, Leu820, Ala719, Met769, Leu768, Phe699, Thr830, 
Figure 2 Schematic workflow summarizing the screening of active compounds against breast cancer.
Abbreviations: aD Vina, autoDockVina; PD, pharmacodynamic; PDB, Protein Data Bank; PK, pharmacokinetic.
Target selection Databases
S-259411474
S-258002927
S-259417539
S-258012947
S-258282355
66,832 compounds
LRo5, druglikeness,
pharmacokinetic filters
Mcule, ZINC, PubChem (~3 million compounds)
Protein preparation
AD Vina
Docking and post-docking analysis
Scoring function (Lamardcian genetic algorithm)
EGFR
Binding
energy –8.9
kcal/mol
PK/PD
filter
Five top hits, multi-target compounds
Adsorption
Distribution
Metabolism
Excretion
Toxicity
Top virtual hits against EGFR (96)
Top virtual hits against HER2 (114)
Top virtual hits against HSP90 (79)
Binding
energy –8.5
kcal/mol
Binding
energy –8.3
kcal/mol
HER2 HSP90
EGFR PDB
ID: 1M17
HER2 PDB
ID: 3RCD
HSP90 PDB
ID: 3TUH
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Leu764, Glu738, Gln767, and Met742 through VdW interac-
tions, respectively. 
Molecular docking studies of her2
The top hits represented high binding energies with HER2 
ranging from −9.4 to −10.3 kcal/mol, as shown in Table 3. 
Post-docking analysis of HER2 revealed that all f ive 
compounds (S-259417539, S-259411474, S-258012947, 
S-258002927, and S-258282355) were also found to bind 
inside the kinase domain, surrounded by interacting residues 
with noticeably high binding energy value that ranged from 
−9.4 to −10.3 kcal/mol (Figure 5). The ligand S-258282355 
was found not to form any H-bond, but alkyl bonds with 
Leu694 and Leu820 were observed as were π-alkyl bonds 
with Lys721, Val702, and Ala719 residues, whereas VdW 
with Ile752, Leu726, Leu800, Thr798, Ser783, Arg784, 
Thr862, Leu852, Asp863, Phe864, Leu755, Gly865, and 
Glu770 were found. The S-258012947 established H-bonds 
Table 1 ADMET profile of potential five multi-targeted virtual hits
ADMET profile S-258282355 S-258012947 S-259417539 S-258002927 S-259411474
BBB penetration + + + + +
hia + + + + +
Caco-2 permeabilty + − − + −
aqueous solubility
−3.9498 −2.1264 −3.7602 −4.5343 −3.7813
P-gp
 substrate
− − + − −
 inhibitor
− − − + +
CYP450 substrate
 CYP450 2C9
− − − − −
 CYP450 2D6
− − − − −
 CYP450 3a4 + + + + +
CYP450 inhibitor
 CYP450 1a2 inhibitor
− − + − −
 CYP450 2C9 inhibitor
− − + − −
 CYP450 2D6 inhibitor + − − − −
 CYP450 2C19 inhibitor
− − + − −
 CYP450 3a4 inhibitor
− − − − −
CYP iP high low high low high
rOCT
− − − − −
Abbreviations: aDMeT, absorption, distribution, metabolism, excretion, and toxicity; BBB, blood–brain barrier; hia, human intestinal absorption; CYP, cytochrome P; 
iP, inhibitory promiscuity; rOCT, renal organic cation transporter; +, present; −, not present.
Figure 3 Chemical structures of lead compounds: (A) s-258002927; (B) s-258012947; (C) s-258282355; (D) s-259411474; (E) s-259417539.
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(Asp863), π-alkyl (Leu694), alkyl (Ala719, Leu820, and 
Met769), and VdW (Asn850, Phe731, Arg849, Gly729, 
Phe864, Gly727, Ser783, Cys805, Gly804, Leu800, 
Met801, Thr798, Leu785, Val797, and Ile752). Similarly, 
H-bond for S-258002927 was found to form H-bonds 
with Asp863 and Cys805, π-alkyl with Ala719, π-sulfur 
with Met774, alkyl bonds with Leu764 and Lys721, and 
VdW with Ile752, Thr798, Thr862, Ser783, Arg784, 
Gln799, Val734, Met801, Leu800, Leu726, Phe1004, and 
Gly804. S-259411474 and S-259417539 were found to 
form H-bonds with Thr862, Thr798, Leu785, Ser783, and 
Asp863, and Lys753, respectively, π-alkyl with Val702, 
Ala719, and Cys773, alkyl with Leu820, Val702, Ala719, 
and VdW with Met801, Gly804, Leu800, Ile752, Val734, 
Asp863, Lys753, Val797, and Asn850, and Phe731, and 
Arg849, Gly729, Phe864, Gly727, Ser783, Cys805, Gly804, 
Leu800, Met801, Thr798, Leu785, Val797, and Ile752 
residues, respectively. 
Table 2 Binding energy and molecular interaction of top five multi-targeted compounds with EGFR
Compound  
molecule ID
Binding energy 
(kcal/mol)
Van der Waals H-bond π-alkyl Alkyl π-sigma
s-258282355
−9.7 arg817, Thr766, gln767, leu768, 
Met769, gly772, Cys773
asn818 leu694, leu820 lys721, Val702, ala719 –
s-258012947
−9.3 ile720, leu764, ile765, Thr766, 
gly772, Cys773, lys721, leu834, 
gly833, gln767, leu768, gly695
asp831 ala719, leu820, Met769 leu694 Val702
s-259417539
−9.1 leu694, Cys751, asp831, lys721, 
leu764, Met742, glu738, asn818, 
arg817
Thr766 ala719 Cys773 leu820
s-259411474
−8.9 ile720, ile765, leu768, leu764, 
leu753, Thr830, asp831, gly695, 
glu738, Cys773, Phe699, gly772
Met769 ala719, Val702 leu820 leu694
s-258002927
−9 gly695, gly772, arg817, Cys773, 
leu820, ala719, Met769, leu768, 
Phe699, Thr830, leu764, glu738, 
gln767, Met742
asp831 Val702 – leu694
Figure 4 Molecular surface representation of egFr with top-ranked multi-targeted virtual hits: (A) s-258002927; (B) s-258012947; (C) s-258282355; (D) s-259411474; 
(E) s-259417539.
Notes: Molecular surface representation of the egFr binding pocket (in blue) with respective ligands in stick format (in purple). alongside each 3D complex, 2D interaction 
plots indicate important binding-site interactions between respective ligands and binding-site residues.
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Molecular docking studies of hsP90
The binding energies of top hits with HSP90 ranged from 
−8.7 to −9.4 kcal/mol, as represented in Table 4, and binary 
interactions are displayed in Figure 6. The binding interac-
tions of S-258002927 with HSP90 included H-bond with 
Thr184, π-alkyl with Ala55, π-sulfur with Met98, and 
VdW with residues Val186, Leu48, Val150, Ser52, Leu107, 
Phe138, Asn51, Val136, Tyr139, Gly135, Gly97, Ile96, 
Lys58, Asp54, Asn106, Lys112, Ala111, and Ser113. H-bond 
for S-258012947 was found with Ala111, alkyl bond with 
Ala111 residue, and VdW with Ile91, Ile26, Val186, Ala55, 
Thr184, Met98, Ser113, Tyr139, Gly135, Val150, Asn106, 
and Leu107 residues. S-258282355 did not form any 
H-bonds; π-alkyl bond was formed with residues Met98 and 
Table 3 Binding energy and molecular interaction of top five multi-targeted compounds with HER2
Compound  
Mcule ID
Binding energy 
(kcal/mol)
Van der Waals H-bond π-sulfur π-alkyl Alkyl π-sigma
s-258282355
−10.3 ile752, leu726, leu800, Thr798, 
ser783, arg784, Thr862, leu852, 
asp863, Phe864, leu755, gly865, 
glu770
– – lys721, Val702, 
ala719
leu694, 
leu820
leu785, 
lys753, 
leu796
s-259411474
−9.8 Met801, gly804, leu800, ile752, 
Val734, asp863, lys753, Val797
Thr862, Thr798, 
leu785, ser783
– ala719, Val702 leu820 leu852
s-258002927
−9.5 ile752, Thr798, Thr862, ser783, 
arg784, gln799, Val734, Met801, 
leu800, leu726, Phe1004, gly804
asp863, Cys805 Met774 ala719 leu764, 
lys721
leu785, 
leu852
s-259417539
−9.4 gly804, Phe1004, Cys805, asn850, 
leu755, leu726, Phe731, gly727, 
Thr862, leu785, Thr798
asp863, lys753 – Cys773 Val702, 
ala719
leu820
s-258012947
−9.4 asn850, Phe731, arg849, gly729, 
Phe864, gly727, ser783, Cys805, 
gly804, leu800, Met801, Thr798, 
leu785, Val797, ile752
asp863 – leu694 ala719, 
leu820, 
Met769
Val702
Figure 5 Molecular surface representation of her2 with respective ligands: (A) s-258002927; (B) s-258012947; (C) s-258282355; (D) s-259411474; (E) s-259417539.
Notes: Molecular surface representation of her2 binding pocket (in blue) with respective ligands in stick format (in purple). alongside each 3D complex, 2D interaction 
plots indicate important binding-site interactions between respective ligands and binding-site residues.
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Ala55, alkyl with Val136 and Ala111, π-sulfur with Met98, 
and VdW with Thr109, Ile110, Lys112, Leu48, Ser113, Ile26, 
Leu107, Tyr139, Gly137, Val186, Phe138, Thr184, Asn106, 
Lys58, Ile96, and Gly97. S-259411474 and S-259417539 
were observed to form H-bonds with Asn51 and Lys58, 
respectively, π-alkyl with Ala111, alkyl bond with Leu107, 
Table 4 Binding energy and molecular interaction of top five multi-targeted compounds with HSP90
Compound 
Mcule ID
Binding energy 
(kcal/mol)
Van der Waals H-bond π-sulfur π-alkyl Alkyl π-sigma
s-259411474
−9.4 ile26, Thr109, Tyr139, Val150, 
Val136, asn106, gly135, ser113, 
ile110, lys112, lys58, gly97, 
ser52, asp93, ile96
asn51 Met98 ala111 leu107, 
Phe138, Val186, 
leu48, ala55
Thr184
s-259417539
−9.2 Val186, ser52, ala55, Met98, 
Val150, asn51, asp54, Thr184, 
asp93, Phe138, leu107, gly137, 
Val136, Tyr139, ser113, lys112, 
ile110
lys58 – ala111 – –
s-258002927
−9.2 Val186, leu48, Val150, ser52, 
leu107, Phe138, asn51, Val136, 
Tyr139, gly135, gly97, ile96, 
lys58, asp54, asn106, lys112, 
ala111, ser113
Thr184 Met98 ala55 – Thr184
s-258282355
−9.1 Thr109, ile110, lys112, leu48, 
ser113, ile26, leu107, Tyr139, 
gly137, Val186, Phe138, Thr184, 
asn106, lys58, ile96, gly97
– Met98 Met98, ala55 Val136, ala111 ala55
s-258012947
−8.7 ile91, ile26, Val186, ala55, Thr184, 
Met98, ser113, Tyr139, gly135, 
Val150, asn106, leu107
ser52, asp93, 
Thr109, ile110
ala111 – ala111 –
Figure 6 Molecular surface representation of hsP90 with respective ligands: (A) s-258002927; (B) s-258012947; (C) s-258282355; (D) s-259411474; (E) s-259417539.
Notes: Molecular surface representation of hsP90 binding pocket (in blue) with respective ligands in stick format (in purple). alongside each 3D complex, 2D interaction 
plots indicate important binding-site interactions between respective ligands and binding-site residues.
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Phe138, Val186, Leu48, and Ala55, π-sulfur with Met98, and 
VdW with Ile26, Thr109, Tyr139, Val150, Val136, Asn106, 
Gly135, Ser113, Ile110, Lys112, Lys58, Gly97, Ser52, 
Asp93, Ile96 and Val186, and Ser52, Ala55, Met98, Val150, 
Asn51, Asp54, Thr184, Asp93, Phe138, Leu107, Gly137, 
Val136, Tyr139, Ser113, Lys112, and Ile110, respectively. 
The current study is an effort to identify anti-breast cancer 
compounds that may be considered for drug development 
to treat breast cancer. The SBVS of ~3 million compounds 
against three EGFR, HER2, and HSP90 proteins has assisted 
in robust screenings of most potential virtual hits. Based on 
the experimentally determined EGFR, HSP90, and HER2 
inhibitors from previous studies, binding energy cutoff to 
select for possible 96, 79, and 114 virtual hits that could act 
on EGFR, HSP0, and HER2 proteins, respectively, was set. 
These virtual hits followed: (a) LRo5 and drug likeness; the 
compounds violating more than one drug-like parameter 
indicated that they might lead to issues with bioavailability, 
and hence, such compounds were not included in the study; 
(b) good HIA and BBB for moderately lipophilic compounds 
to cross the BBB, whereas polar molecules are poor central 
nervous system drugs; and (c) comprehensive ADMET 
profile. The best possible orientations forming stable ligand–
target protein complexes, through the process of molecular 
docking, were achieved.
The binding energy of the ligand and its half-life quanti-
fies the efficiency of the ligand–protein complex. The rate 
of dissociation is rapid for weaker interactions; however, the 
rate of dissociation slows down with an increase in the value 
of binding energy.58 Compounds with a longer half-life have 
strong binding energies, and hence, they take a longer time 
to dissociate. Strong interactions between residues imply that 
binding with inhibitory compounds may be stable, leading to 
an inhibitory reaction. The top five best virtual hits in com-
plex with EGFR, HER2, and HSP0 revealed strong binding 
affinities and highlighted several H-bonds and hydrophobic 
interactions between functional groups, and side chains of 
essential residues. Post-docking analysis of EGFR, HER2, 
and HSP90 with these hits disclosed more in-depth details. 
The EGFR that complexed with S-259429764 showed the 
highest binding energy (−10.7 kcal/mol). Other compounds 
showed binding energy in the range from −10.7 to −8.7 kcal/
mol. Moreover, common interacting residues that displayed 
VdW and H-bond with different compounds were Gln767, 
Leu768, Gly772, Cys773, Leu764, Gly695, and Thr830, 
respectively (Table 2). However, the HER2 complexed with 
S-258282355 showed the highest binding energy (−10.3 kcal/
mol), and other compounds showed binding energy in the 
range from −9.8 to −8.9 kcal/mol. Together with this, the 
common interacting residues that displayed VdW and H-bond 
with different compounds were Ile752, Leu726, Leu800, 
Thr798, Ser783, Thr862, Met801, and Asp863, respectively 
(Table 3). Likewise, HSP90 complexed with S-259411474 
showed the highest binding energy (−9.4 kcal/mol) and dis-
played H-bonds with Asn106 and Ser50. Other compounds 
showed binding energy in the range from −9.4 to −8.3 kcal/
mol. Interestingly, all compounds interacted equally in terms 
of VdW interactions with Tyr139 and Ser113 of HSP90. Other 
common interacting residues were Val150, Asn106, Lys112, 
Val136, Gly135, Ile110, Lys58, Ser52, and Gly97 that dis-
played VdW interactions with different compounds (Table 4).
Furthermore, all screened virtual hits predicted promising 
ADMET profile, and their strong binding affinity stipulated 
the multi-targeted potential of these top virtual hits. 
Conclusion
Breast cancer is one of the leading cancer types in women 
across the globe. Computational tools have been widely used 
for drug development and discovery of multi-targeted inhibi-
tors of many overexpressed proteins induced in breast cancer. 
This study reveals five multi-targeted compounds that possess 
high binding energies against most common target proteins 
that are involved in breast cancer. With excellent PK and PD 
properties as predicted, these virtual hits may be considered 
for early drug development against breast cancer after being 
tested through in vitro and in vivo studies.
Disclosure
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